Proceedings of the National Academy of Sciences · 31 July 2026 · From issue 15
High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies
Blocking antibodies in myasthenia gravis patients raised the risk of severe COVID pneumonia up to 12 times.
Adrian Gervais, Astrid Marchal et al.
Integrity screen: passed (3 checks) Checked 3 August 2026. Read the source
The plain-language reading of this paper is in the full issue, for subscribers.
Read the full issue